CN Patent

CN111542317A — 用于治疗或预防细胞增殖性疾病的香豆素衍生物

Assigned to Royal Cancer Hospital Cancer Research Institute · Expires 2020-08-14 · 6y expired

What this patent protects

本发明提供了用于治疗或预防细胞增殖性疾病的药物，所述药物包含由下式表示的化合物或其药用盐作为活性成分，其中所述药物以这样的方式使用：(a)每周两次地施用所述化合物或盐，持续3周，(b)在接下来的1周中暂停所述化合物或盐的施用，并且(c)随后将步骤(a)和(b)重复至少一次。

USPTO Abstract

本发明提供了用于治疗或预防细胞增殖性疾病的药物，所述药物包含由下式表示的化合物或其药用盐作为活性成分，其中所述药物以这样的方式使用：(a)每周两次地施用所述化合物或盐，持续3周，(b)在接下来的1周中暂停所述化合物或盐的施用，并且(c)随后将步骤(a)和(b)重复至少一次。

Drugs covered by this patent

Patent Metadata

Patent number: CN111542317A
Jurisdiction: CN
Classification: —
Expires: 2020-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Royal Cancer Hospital Cancer Research Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.